Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN 1/20 vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism in gut and liver. Norethindrone: primarily metabolized by reduction and conjugation; substrate of CYP3A4.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Norethindrone: 61% (albumin, SHBG); Ethinyl estradiol: 97% (albumin).
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Norethindrone: 3.8 L/kg; Ethinyl estradiol: 2.8 L/kg. Indicates extensive tissue distribution.
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: Norethindrone 64% (first-pass metabolism); Ethinyl estradiol 38-48% (first-pass metabolism).
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to potential fluid retention and metabolic acidosis.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in acute hepatic disease, hepatic adenomas, or severe cirrhosis (Child-Pugh class C). No specific dose adjustments provided for mild to moderate impairment; use caution.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 21 days followed by 7 placebo days.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated for use after menopause. No specific dose adjustments in elderly; increased risk of thrombosis and hypoglycemia warrants caution.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should not smoke.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders: discontinue if thrombophlebitis, thromboembolic, or vascular events occur,Carcinoma risk: increased risk of breast cancer; cervical cancer association,Hepatic effects: acute liver disease, liver tumors,Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions: retinal thrombosis; discontinue if unexplained vision loss,Hereditary angioedema exacerbation,Chloasma,Pregnancy: discontinue if pregnancy occurs
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women >35 years
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
Grapefruit and grapefruit juice may increase estrogen levels; limit intake. No other significant food interactions. Avoid St. John's wort (herbal supplement) as it reduces contraceptive efficacy. Alcohol may increase risk of liver toxicity; moderate consumption is generally acceptable.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
LARIN 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from low-dose OCs in cohort studies, but an increased risk of cardiovascular malformations (e.g., VSD, TGA) and neural tube defects has been suggested in some studies; risk of oral cleft is not increased. Second/third trimesters: Use may increase risk of fetal hepatic adenoma, fetal feminization with androgenic progestins (norethindrone has minimal androgenicity), and potential for neonatal withdrawal bleeding or hormonal effects; no clear risk of pregnancy loss beyond baseline.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; combined OCs are generally not recommended during breastfeeding, especially in early lactation, as they may reduce milk quantity and quality. M/P ratio: Not established for LARIN 1/20; ethinyl estradiol M/P ratio is ~0.2-0.4, norethindrone M/P ratio ~0.1. Infants exposed via milk show no significant adverse effects, but theoretical risks include jaundice, breast enlargement, and long-term carcinogenicity. Use of progestin-only contraceptives is preferred.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
LARIN 1/20 is contraindicated in pregnancy; no dose adjustment recommended because drug should be discontinued immediately if pregnancy is detected. Pharmacokinetic changes in pregnancy (e.g., increased clearance, decreased SHBG, increased volume of distribution) would theoretically require higher doses if used, but use is not indicated. No standard dosing for use during gestation.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
LARIN 1/20 (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) has a low estrogen dose, which may reduce estrogen-related side effects but can increase breakthrough bleeding. It is a monophasic pill. Starting on the first day of menses provides immediate contraceptive protection. Caution in patients with migraine with aura or uncontrolled hypertension. Check for drug interactions with CYP3A4 inducers (e.g., rifampin, St. John's wort).
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one pill daily at the same time; missing pills increases pregnancy risk.,If you miss a pill, follow the package instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Do not smoke while taking this medication, especially if over 35; smoking increases risk of serious cardiovascular events.,This pill does not protect against STIs; use condoms for protection.,Inform your healthcare provider of all medications and supplements you take, especially St. John's wort, antibiotics, and anticonvulsants.,Contact your doctor if you experience severe headache, chest pain, leg pain or swelling, sudden shortness of breath, or vision changes.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN 1/20 vs LARIN 1.5/30, answered by our medical review team.
LARIN 1/20 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN 1/20 and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN 1/20 is: One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN 1/20 and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN 1/20 is classified as Category C. LARIN 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from low-dose OCs in cohort studies,. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.